Synopsis: Dr. Reddy’s Laboratories has received a strategic boost after its partner secured Health Canada approval for Semaglutide Injection, strengthening its position in the high-growth peptide segment. However, the company’s recent quarterly performance shows stable revenue growth but pressure on profitability, reflecting a mixed operational trend.
Dr. Reddy’s Laboratories is one of India’s leading pharmaceutical companies with a strong global presence across generics, APIs, and specialty products. The company continues to focus on complex generics and regulated markets, while expanding its capabilities in high-value therapies such as peptides and injectables.
As of today, Dr. Reddy’s Laboratories is trading at Rs. 1,332, with a market capitalization of Rs. 1,11,164 crore and the stock shows downward momentum of 2% as compared to previous close of Rs. 1,354. The stock has recorded a 52-week high of Rs. 1,380 and a low of Rs. 1,121, indicating relatively stable price movement.
The company announced that its partner has received Health Canada approval for Semaglutide Injection, a generic version of the blockbuster drug Ozempic. Dr. Reddy’s plays a crucial role as a development and manufacturing partner, providing scale-up and commercial manufacturing support. This approval is significant as Semaglutide belongs to a rapidly growing segment in diabetes and obesity treatment, which could drive future revenue growth.
In Q3 FY26 (December 2025), the company reported revenue of Rs. 9,022 crore, reflecting a 5.8% YoY growth. However, profitability remained under pressure, with net profit declining to Rs. 1,210 crore, down 14.4% YoY. Operating profit stood at Rs. 1,887 crore, indicating margin compression despite steady topline growth.
In Q4 FY26 (March 2026), Dr. Reddy’s reported revenue of Rs. 9,050 crore, showing a marginal 0.3% QoQ growth compared to Rs. 9,022 crore in Q3, indicating stable business performance. On a year-on-year basis, revenue improved significantly compared to Rs. 7,311 crore in Q4 FY25, reflecting continued demand strength.
On the profitability front, net profit trends remained under pressure, as the company had reported higher profitability in earlier quarters, while Q3 net profit stood at Rs. 1,210 crore. However, operating profit improved to Rs. 1,997 crore in Q4, compared to Rs. 1,887 crore in Q3, suggesting some recovery at the operating level.
Dr. Reddy’s Laboratories continues to show steady revenue growth supported by its diversified portfolio and strong global presence, although profitability remains under pressure in the near term. The recent Semaglutide approval provides a strong strategic advantage and long-term growth opportunity.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Dr. Reddy’s Q4 Operating Profit Grows to ₹1,997 Cr; Semaglutide Approval Offers Long-term Upside appeared first on Trade Brains.